Cognition Therapeutics Inc (CGTX) Stock Analysis
Verdict: HOLD
Insider cluster buying and a 3-quarter earnings beat streak collide with a 15-month cash runway, making clinical data the binary pivot.
Investment score: 62/100
Analysis as of
Is Cognition Therapeutics Inc stock worth reviewing? The TradeMates thesis
CGTX is a speculative momentum play backed by strong insider conviction and a recent patent catalyst.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Cognition Therapeutics Inc opportunities and risks
What speaks for CGTX
- Insider Conviction Alignment
What speaks against CGTX
- Imminent Financing Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CGTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -19.0% |
| GRIN.CN | n/a | 3.0x | 37.3x | 43.8% | 0.9% | -0.1% |
| RFL | n/a | 102.4x | n/a | 74.4% | -3321.7% | -31.9% |
| NTHI | n/a | 0.0x | n/a | 0.0% | 0.0% | -20.6% |
| JUSH.CN | n/a | 0.4x | 9.4x | 43.1% | -26.9% | 17.9% |
| CWEB.TO | n/a | 1.0x | n/a | 42.4% | -75.1% | -29.5% |
| Peer median | n/a | 1.0x | n/a | 43.1% | -26.9% | -20.6% |
Frequently asked questions about Cognition Therapeutics Inc (CGTX)
Is CGTX stock a good investment?
The TradeMates model rates Cognition Therapeutics Inc as HOLD with an investment score of 62/100. CGTX is a speculative momentum play backed by strong insider conviction and a recent patent catalyst. This is algorithmic model output, not personal investment advice.
Is CGTX stock a buy?
The TradeMates model verdict for CGTX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.